SCHEMBL905401

SCHEMBL905401

COC(=O)CCCCCCCCCCCNC(=O)CCCC(=O)O

nearest known ligand 0.66

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 4/20 0.66
▸ EPHX2 P34913 7/20 0.56
▸ ADRA1A P35348 1/20 0.55
▸ PRMT1 Q99873 1/20 0.53
▸ RECQL P46063 1/20 0.52
▸ LMNA P02545 2/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ PLA2G2A P14555 1/20 0.46
▸ CASP2 P42575 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18631906 0.98 TSHR (0.62) TSHREPHX2ADRA1APRMT1RECQL
SCHEMBL28440634 0.96 TSHR (0.64) TSHREPHX2ADRA1APRMT1RECQL
SCHEMBL13376980 0.91 RECQL (0.61) TSHREPHX2RECQLLMNAL3MBTL1
SCHEMBL2771342 0.89 RECQL (0.63) TSHREPHX2RECQLLMNAL3MBTL1
SCHEMBL15399777 0.89 TSHR (0.65) TSHREPHX2RECQLLMNAL3MBTL1
SCHEMBL13405232 0.87 TSHR (0.53) TSHREPHX2ADRA1APRMT1RECQL
SCHEMBL16620817 0.87 RECQL (0.61) TSHREPHX2RECQLLMNAL3MBTL1
SCHEMBL28757328 0.87 PRMT1 (0.68) TSHREPHX2ADRA1APRMT1LMNA
SCHEMBL24483715 0.85 PRMT1 (0.71) TSHREPHX2ADRA1APRMT1LMNA
SCHEMBL22506195 0.85 PRMT1 (0.71) TSHREPHX2ADRA1APRMT1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2264065-B1 NOVEL INSULIN DERIVATIVES NOVO NORDISK AS (DK) 2017-03-08 — — EP disclosed
US-20140349925-A1 NOVEL INSULIN DERIVATIVES NOVO NORDISK AS (DK) 2014-11-27 — — US disclosed
US-8828923-B2 Insulin derivatives NOVO NORDISK A/S (DK) 2014-09-09 — — US disclosed
EP-2275439-B1 Novel insulin derivatives NOVO NORDISK AS (DK) 2014-03-26 — — EP disclosed
EP-2107069-B1 Novel insulin derivatives NOVO NORDISK AS (DK) 2013-01-16 — — EP disclosed
EP-2287184-A2 Novel insulin derivatives NOVO NORDISK A/S (DK) 2011-02-23 — — EP disclosed
EP-2275439-A2 Novel insulin derivatives NOVO NORDISK A/S (DK) 2011-01-19 — — EP disclosed
EP-2264065-A2 Novel Insulin Derivatives NOVO NORDISK A/S (DK) 2010-12-22 — — EP disclosed
EP-2264066-A2 Novel insulin derivatives NOVO NORDISK A/S (DK) 2010-12-22 — — EP disclosed
US-20100009899-A1 Novel Insulin Derivatives NOVO NORDISK A/S (DK) 2010-01-14 — — US disclosed
US-7615532-B2 Antidiabetic agents; insulin derivatives which are naturally occurring insulins or analogues thereof which have a side chain attached either to the alpha-amino group of the N-terminal amino acid residue of the B chain or to epsilon-amino group of a Lys residue present in the B chain of parent insulin NOVO NORDISK A/S (DE) 2009-11-10 — — US disclosed
EP-2107069-A2 Novel insulin derivatives NOVO NORDISK A/S (DK) 2009-10-07 — — EP disclosed
US-20060183668-A1 Antidiabetic agents; insulin derivatives which are naturally occurring insulins or analogues thereof which have a side chain attached either to the alpha-amino group of the N-terminal amino acid residue of the B chain or to epsilon-amino group of a Lys residue present in the B chain of parent insulin NOVO NORDISK A/S (DK) 2006-08-17 — — US disclosed
EP-1660531-A2 NOVEL INSULIN DERIVATIVES NOVO NORDISK A/S (DK) 2006-05-31 — — EP disclosed
WO-2005012347-A2 NOVEL INSULIN DERIVATIVES NOVO NORDISK A/S (DK) 2005-02-10 — — WO disclosed
Send feedback